Novo amps up 2012 expectations on strong Victoza sales

Novo Nordisk ($NVO) boosted its sales outlook for 2012 after sales of the diabetes drug Victoza more than doubled to 2.1 billion crowns, beating analyst estimates. It's counting on new long-acting insulins that are awaiting approval to help it compete with Amylin Pharmaceuticals' ($AMLN) newly approved weekly injection Bydureon. Report